Hi SkyDi, in defense of Bripoz and his post that you refer to, I do not believe Bripoz infers that others "aren't quite as noble as [he]". The sentiment, in fact, echoes my previous post... that the offer by Merck is low and undervalues the company and Cavatak. However, if a higher bid is not forthcoming, do we really want to go back to the drawing board (as shareholders)? Do we really want to hold back the real opportunity to progress this cancer treatment at a faster pace from the cancer sufferers?
Would voting down the offer be constructive to the current shareholders? Take the emotion out of it, as Bripoz infers... what would happen to the shareholders' values? Other pharmas have months to consider their position and to make counter-offers if they believe VLA is worth more. In a way, it is irrelevant what we (the retail shareholders) believe is the true value. IMO, I can't see the sp holding at these levels if the offer is knocked back. Whilst we may be the leader in this field currently... there are that many now in this arena (nipping out our heels) to make Cavatak "old technology".
If anything, I believe your post, SkyDi, to be highly emotive and a little offensive. Please keep it real. Time and the market will tell us if $1.75 is lowball or not. I too would hate to see VLA go back on the merry-go-round especially after experiencing the sp drop from $1.35 to 60c recently. It would not be a wise move to vote down the offer in the absence of another.
Cheers - Shellbell
VLA Price at posting:
$1.70 Sentiment: Hold Disclosure: Held
